Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer
Status:
Active, not recruiting
Trial end date:
2025-08-31
Target enrollment:
Participant gender:
Summary
This research study is studying a drug called Neratinib with and without Fulvestrant as
possible treatments for HER2-positive breast cancer .
The interventions involved in this study are:
- Neratinib and Fulvestrant
- Neratinib alone